Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy

Fig. 2

Reconstructed 3D images of the 2nd lumbar vertebrae also showing a noticeable difference in bone mass between the control (a) and treatment group (b). Similar to the distal femur, (c) bone volume (BV/TV), (d) trabecular number (Tb.N) and (e) volumetric bone mineral density (vBMD) were increased while (f) trabecular separation (Tb. Sp) was decreased in ActRIIB-Fc-treated mice compared to controls. ActRIIB-Fc and running did not result in further beneficial effect. # = p < 0.05 compared to PBS, * = p < 0.05 compared to PBS-R

Back to article page